Cerus -

9/2/10
Cerus and the Swiss Red Cross Report Successful Outcome of INTERCEPT Blood System... more >

8/24/10
Cerus Signs Agreement to Acquire INTERCEPT Blood System Asian Commercial Rights... more >

7/29/10
Cerus Corporation Reports Second Quarter Revenues more >

About Cerus Corporation

2010 Annual Meeting

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is currently in clinical development.
> More about Cerus

Meeting information and 2009 Annual Report are now available.

> Information & downloads